Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod for active axial spondyloarthritis/ankylosing spondylitis
ChiCTR1800019227Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) comparing Iguratimod with Placebo control (2 arms). Primary endpoints: Clinical improvement by ASDAS, ASAS20 response and 11 more. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
iguratimod
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR1800019227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019227.